PLD3 Downregulation for Axonal Spheroid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Alzheimer's disease and other neurodegenerative conditions focus on extracellular amyloid removal, but the cellular mechanisms linking beta-amyloid deposition to neural network disruption are not well understood, limiting the design of effective treatments for conditions like Alzheimer's, ALS, Huntington's, and Parkinson's diseases.
Innovation Solution
A method involving compounds that downregulate the expression or activity of PLD3, such as small molecule inhibitors, protein inhibitors, or CRISPR components, to prevent or reverse the formation and enlargement of axonal spheroids, which block action potential propagation, thereby addressing the neurodegenerative conditions by targeting PLD3 in neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If extracellular amyloid removal strategies are used, then amyloid plaque burden is reduced, but the cellular mechanisms linking Aβ deposition to neural network disruption remain unaddressed
Solution Approach 1:
The patent extracts and isolates the specific cellular mechanism (PLD3-mediated axonal spheroid formation) from the complex cascade of events following Aβ deposition. By focusing on this extracted mechanism, the invention provides a targeted therapeutic approach that addresses the cellular underpinnings rather than just the extracellular amyloid burden.
Solution Approach 2:
Instead of continuing to focus on removing extracellular amyloid (the conventional approach), the patent inverts the therapeutic strategy by targeting the intracellular cellular mechanism (PLD3 and axonal spheroids) that actually causes neural dysfunction. This inversion shifts the focus from the cause (Aβ deposition) to the effect (axonal spheroid formation and conduction block).
2Quantity of substance
If axonal spheroids form and enlarge, then PLD3 activity increases, but action potential propagation is blocked
Solution Approach 1:
The patent applies preliminary anti-action by using compounds that downregulate PLD3 expression or activity before axonal spheroids can form and enlarge. This preventive approach blocks the pathological process at its origin, preventing the conduction block before it occurs rather than attempting to reverse it after formation.
Solution Approach 2:
The invention changes the critical parameter of PLD3 expression level or activity through pharmacological or genetic intervention. By downregulating PLD3, the patent alters the cellular state to prevent axonal spheroid formation, thereby maintaining reliable action potential propagation despite the presence of amyloid plaques.
3Shape
If PLD3 expression is downregulated, then axonal spheroid formation is reduced, but neural network abnormalities are ameliorated
Solution Approach 1:
The patent converts the harmful effect of PLD3 (which drives axonal spheroid formation and conduction block) into a beneficial therapeutic target. By downregulating PLD3, the invention transforms the pathological process into a treatable condition, where reducing PLD3 expression actually benefits neural network function and reverses cognitive decline.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The downregulation of PLD3 reduces the size of axonal spheroids, restoring axonal conduction properties and potentially ameliorating neural network abnormalities in Alzheimer's disease and other neurodegenerative conditions without the need for amyloid plaque removal.
Implementation Method 1
an expression vector comprising an expression cassette, wherein the expression cassette expresses CRISPR components that downregulate the expression level and/or activity of PLD3 by CRISPR knockout or CRISPR knockdown
Implementation Method 2
the compound that downregulates the expression level or the activity of PLD3 comprises a nucleic acid that downregulates the expression level and/or activity of PLD3 by RNA interference
Data Source
AI summary
Described herein is a method of reversing or preventing a formation or enlargement of an axonal spheroid. The method includes introducing into a neuron affected by formation or enlargement of the axonal spheroid a compound that downregulates PLD3 expression level or activity. Also described herein is a method of treating or preventing a neurodegenerative condition in a subject in need thereof. The method includes administering to the subject a compound that downregulates PLD3 expression level or activity in a neuron cell affected by the neurodegenerative condition. Further described herein is a pharmaceutical composition for treating a neurodegenerative condition in a subject. The pharmaceutical composition includes a compound that downregulates PDL3 expression level or activity in a neuron cell affected by the neurodegenerative condition; and a pharmaceutically acceptable carrier.